US: BPMUF - Basilea Pharmaceutica AG

Yield per half year: +5.35%
Dividend yield: 0.00%

Share chart Basilea Pharmaceutica AG

Extended chart Simple chart
Financial Markets by TradingView

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections.

more details
In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 7.17
Дивиденд ао 5.38
Сайт https://www.basilea.com
Цена ао 54
Change price per week: +2.21% (52.83)
Change price per month: +2.21% (52.83)
Change price per 3 month: +2.21% (52.83)
Change price per half year: +5.35% (51.26)
Change price per year: +32.52% (40.75)
Change price per 3 year: +31.71% (41)
Change price per 5 year: -9.4% (59.6)
Change price per year to date: +2.21% (52.83)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % 0 0
ROE, % 0 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.5 5
Total: 2.35

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 32.76 5
Yield Ebitda, % -283.67 0
Yield EPS, % -205.18 0
Total: 1
More

Head Job title Payment Year of birth
Mr. David Veitch Chief Executive Officer 1965 (60 years)
Mr. Adesh Kaul Chief Financial Officer 1974 (51 year)
Dr. Gerrit Hauck Ph.D. Chief Technology Officer 1964 (61 year)
Dr. Laurenz Kellenberger Ph.D. Chief Scientific Officer 1967 (58 years)
Dr. Marc Engelhardt M.D. Chief Medical Officer 1964 (61 year)
Dr. Peer Nils Schroder Head of Corporate Communications & Investor Relations
Mr. Damian Heller General Counsel & Corporate Secretary 1966 (59 years)
Mr. Andreas Kumin Head of Corporate Development
Ms. Ursula Eberhardt Head of Global Human Resources 1962 (63 years)
Mr. Mark Jones Ph.D. Head of Global Affairs 1968 (57 years)

Address: Switzerland, Allschwil, Hegenheimermattweg 167b - open in Google maps, open in Yandex maps
Website: https://www.basilea.com